282 (PB062) - Optimization of treatment schedule for the ATR inhibitor elimusertib (BAY 1895344) in preclinical tumor models

Abstract

Background: ATR kinase is a critical component of the DNA damage response (DDR) machinery. Elimusertib, a potent and selective ATR inhibitor, has demonstrated efficacy in preclinical tumor models as monotherapy and synergistic antitumor activity in combination with DNA damage inducing as well as DNA repair compromising therapies. Elimusertib monotherapy revealed clinical benefit in patients with advanced solid tumors carrying DDR defects (Yap et al. Cancer Discovery 2021; Yap et al. AACR Annual Meeting 2022).